OMER - オメロス (Omeros Corporation) オメロス

 OMERのチャート


 OMERの企業情報

symbol OMER
会社名 Omeros Corp (オメロス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オメロス(Omeros Corporation)はバイオ医薬品会社である。同社は大規模市場、炎症、凝固障害及び中枢神経系の障害を標的とする孤児の適応症のための小分子及びタンパク質治療薬の発見、開発、商業化に従事する。白内障手術と眼内レンズ(IOL)の交換時に市販されている医薬品Omidria(フェニレフリンとケトロラク注射)が使用される。Omidriaは、眼科的、関節鏡的、泌尿器科学的及び他の外科的処置を受けている患者のために設計されたPharmacoSurgeryプラットフォームに由来する。PharmacoSurgeryプラットフォームは、米国食品医薬品局(FDA)が承認した治療薬の低用量の組み合わせに基づいて、手術中に炎症と先天性外傷による他の問題を抑制するための手術期間中、 手術中及び手術後の両方で臨床的補助を提供する。   オメロスは米国のバイオ医薬品企業。炎症、凝固障害、中枢神経系障害の治療薬の開発、商品化に従事。眼科学向けOMS302、関節鏡処置OMS103HP、泌尿器科向けOMS201、認知障害OMS824、虐待依存症向けPPARg Programなどの臨床プログラムを手掛けるほか、運動障害治療向けOMS527などの前臨床プログラムを手掛ける。   Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
本社所在地 201 Elliott Avenue West Seattle WA 98119 USA
代表者氏名 Gregory A. Demopulos グレゴリーA.デモプス
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 206-676-5000
設立年月日 34486
市場名 NASDAQ National Market System
ipoyear 2009年
従業員数 173人
url www.omeros.com
nasdaq_url https://www.nasdaq.com/symbol/omer
adr_tso
EBITDA EBITDA(百万ドル) -76.79100
終値(lastsale) 14.75
時価総額(marketcap) 716257286
時価総額 時価総額(百万ドル) 770.15870
売上高 売上高(百万ドル) 38.66000
企業価値(EV) 企業価値(EV)(百万ドル) 812.11270
当期純利益 当期純利益(百万ドル) -87.78300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Omeros Corporation revenues decreased 89% to $3.2M. Net loss increased from $29.4M to $63.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 55% to $35.2M (expense) Interest expense increase of 21% to $6.5M (expense).

 OMERのテクニカル分析


 OMERのニュース

   Global Opioid Use Disorder Market (Covid 19 Update) Future Growth Analysis, Business Demand and Opportunities to 2027 || Teva Pharmaceutical Industries Ltd.; Omeros Corporation; Camurus; Hikma Pharmaceuticals PLC; Titan Pharmaceuticals, Inc  2020/10/22 10:13:20 OpenPR
Data Bridge Market Research has recently added a concise research on the Global Opioid Use Disorder Market- Industry Trends and Forecast to 2026. A reliable Global Opioid Use Disorder Market report contains market data that can be relatively essential when
   Omeros (NASDAQ:OMER) Earns Buy Rating from Analysts at Bank of America  2020/10/20 12:45:05 Zolmax News
Analysts at Bank of America started coverage on shares of Omeros (NASDAQ:OMER) in a report issued on Tuesday, The Fly reports. The firm set a “buy” rating on the biopharmaceutical company’s stock. Several other analysts also recently commented on the stock. HC Wainwright reduced their target price on shares of Omeros from $34.00 to $32.00 […]
   Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit  2020/10/16 12:30:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The presentation about the inhibition of the alternative pathway by targeting MASP-3 was made by Jason Cummings, Ph.D., Omeros’ Associate Directo
   Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA  2020/10/15 12:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be presented in a webcast on Thursday, October 22, 2020 at 8:30 a.m. ET by Miguel Perales, M.D, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, and Alessandro Rambaldi, MD, Professor, Department of Oncology and
   Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs  2020/10/01 13:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. The two-year extension of pass-through status provided by Congress through the Consolidated Appropriations Act of 2018 for OMIDRIA expired today. Omeros is actively engaged in requesting from the Centers for Medicare and Medicaid Services (CMS) and the Department of Health and Human
   Omeros’ Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress  2020/06/11 12:45:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the virtual edition of the 25th annual European Hematology Association Congress. The presentation, entitled Narsoplimab (OMS721) for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy, will be d
   Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress  2020/05/14 13:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2020. This year the congress will be held virtually. The presentation, entitled Narsoplimab (OMS721) for the Treatment of Adult Hematopoietic Stem Cell Transplant-
   Should You Buy Omeros (OMER) Ahead of Earnings?  2020/05/08 12:36:00 Zacks Investment Research
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020  2020/05/05 11:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2020, on Monday, May 11, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone, ple
   Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results  2020/03/02 21:03:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and
   Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results  2020/03/02 21:03:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and
   Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA  2020/03/02 21:01:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint. While an overview of preliminary data submitted to FDA was made public on December 4, 2019 in a press release from the company, all patients have now completed treatment and tr
   Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020  2020/02/24 12:00:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conferen
   Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors  2020/02/11 13:30:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.com, Inc., to Omeros’ Board of Directors. He will also serve in a consulting role at Omeros. Mr. Zumwalt brings significant expertise in developing comprehensive business relationships with major banks and financial institutions. A 15-year veteran of Amazon, Mr. Zumwalt was responsible for managing the company’s cash, investments and debt financings, in
   The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares  2020/02/04 12:51:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) ( announced a deal to buy cell and gene therapy CDMO MasTherCell and forecast-beating second quarter results) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Molecular Templates Inc (NASDAQ: MTEM ) Orgenesis Inc (NASDAQ: ORGS ) (announced sale of subsidiary MasTherCell to Catalent) Profound Medical Corp (NASDAQ: PROF ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) Theravance Biopharma Inc (NASDAQ: TBPH ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 3.) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Avanos Medical Inc (NYSE: AVNS ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) (moved along with China pharmaceutical stocks due to coronavirus) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) I-Mab (NASDAQ: IMAB ) (went public in mid-January) Intec Pharma Ltd (NASDAQ: NTEC ) TapImmune Inc. (NASDAQ: MRKR ) Omeros Corporation (NASDAQ: OMER ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オメロス OMER Omeros Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)